Formulary Advantages Among Monoclonal Antibodies in Oncology: Health plans report high priority on reducing oncology drug costs.
While we forecast sales of oncology drugs in the United States to grow at a compound annual growth rate of 4.4% between now and 2016, we forecast sales of monoclonal antibodies (MAbs) in oncology to grow at a CAGR of 6.7% over that same time period. This disproportionate growth in spending on MAbs in oncology, combined with the efficacy of these agents versus life-threatening diseases, will lead to increasing pressure on payers' budgets.
Using tiering and restrictions data from Fingertip Formulary, as well as insight from 50 pharmacy directors, this report determines the key trends in reimbursement of MAbs in oncology, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition and provides insight for stakeholders looking to capitalize on future shifts in coverage in order to better position their products among competitors.
